Concentra Biosciences offers $3/share + CVR for Acelyrin, outperforming Alumis' bid. Read why I rate SLRN stock a Sell at ...

Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) had its price target lowered by Jefferies Financial Group from $70.00 to $53.00 in a research report report published on Tuesday,Benzinga reports.

Benitec Biopharma Inc. (NASDAQ:BNTC – Get Free Report) crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $11.29 and traded as high as $13.45.

Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan reports 2024 financial results, enhancing operational resilience amid challenging conditions Financial ...

Officers, beneficial owners, and other insiders have shelled out more than $10 million on each of these four biotech stocks ...

We recently published a list of Top 10 Stocks Everyone Is Talking About These Days. In this article, we are going to take a ...

Fintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Zymeworks (NasdaqGS:ZYME) with a Outperform ...

The diabetes and weight loss drug market is heating up in 2025, with significant growth signs everywhere. According to a recent study from Research and Markets, industry growth is running at an ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

While the job market is tough for life sciences professionals right now, it won’t always be. Employers must continue striving ...

Learn more about whether Kymera Therapeutics, Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...

Stevanato's 2024 revenue hits €1.1B, driven by biopharma growth! Discover how facility expansions & rising demand are ...